<DOC>
	<DOCNO>NCT02558972</DOCNO>
	<brief_summary>Vasovagal syncope ( VVS , simple faint ) common cause transient loss consciousness represent acute episodic form orthostatic intolerance ( OI ) . Postural tachycardia syndrome ( POTS ) common chronic form OI . Both define debilitating symptom sign upright relieve recumbency . Northera therefore improve sympathetic splanchnic arterial vasoconstriction sympathetic splanchnic venoconstriction POTS VVS , may represent ideal drug improve orthostatic response POTS VVS .</brief_summary>
	<brief_title>Northera Improves Postural Tachycardia Syndrome ( POTS ) Postural Vasovagal Syncope ( VVS )</brief_title>
	<detailed_description>Vasovagal syncope ( VVS , simple faint ) common cause transient loss consciousness represent acute episodic form orthostatic intolerance ( OI ) . Postural tachycardia syndrome ( POTS ) common chronic form OI . Both define debilitating symptom sign upright relieve recumbency . Pathophysiological mechanism remain elusive . Most POTS patient VVS patient normal supine rest hemodynamics excessively redistribute blood flow blood volume central pool splanchnic vasculature defective splanchnic arterial vasoconstriction venoconstriction . While peripheral splanchnic arterial vasoconstriction depend primarily post-junctional alpha-1 adrenergic receptor , splanchnic venoconstriction also depend post-junctional alpha-2 adrenergic receptor . Consequently , selective alpha-1 agonist midodrine may produce sufficient splanchnic venoconstriction compensate splanchnic pool POTS VVS . Such alpha adrenergic subtype restriction apply Northera ( droxidopa ) norepinephrine ( NE ) prodrug therefore increase amount synaptic NE bind alpha-2 alpha-1 receptor . Northera therefore improve sympathetic splanchnic arterial vasoconstriction sympathetic splanchnic venoconstriction POTS VVS , may represent ideal drug improve orthostatic response POTS VVS . We test hypothesis Northera , appropriate dose , improve splanchnic adrenergic deficit initiate POTS postural VVS sufficient daily dose improves quality life patient . To accomplish , investigator recruit 10 POTS patient age 18-30 year , 10 similarly age patient 2 episode VVS past year ( thus define recurrent VVS ) 10 age gender match healthy volunteer control subject follow specific aim :</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Syncope</mesh_term>
	<mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
	<mesh_term>Syncope , Vasovagal</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>Both male female participant study Ages 1830 year old POTS case refer daytoday Orthostatic Intolerance ( OI ) â‰¥3 symptom &gt; 6 month . POTS confirm medical history indicate chronic OI , prior 700 tilt table test stand test show excessive tachycardia symptom OI absence hypotension . VVS ( faint ) subject least 2 episode postural VVS past calendar year . Healthy volunteer include Study # 1 Only free systemic illness eligible participate . This exclude patient illness associated autonomic dysfunction diabetes , renal disease , congestive heart failure , systemic hypertension , acute chronic inflammatory disease , neoplasm , immune mediate disease , trauma , obesity , cancer , supine upright hypertension , peripheral vascular disease . No subject take neurally active , vasoactive drug . Prior medication stop least 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Postural Tachycardia Syndrome ( POTS )</keyword>
	<keyword>Vasovagal Syncope ( VVS )</keyword>
	<keyword>Fainting</keyword>
	<keyword>Orthostatic Intolerance</keyword>
	<keyword>Droxidopa</keyword>
	<keyword>Northera</keyword>
</DOC>